Complement-mediated tumour growth: Implications for cancer nanotechnology and nanomedicines

Molecular Immunology

Volumn 46, Issue 8-9, 2009, Pages 1571-1572

  Moghimi, S M ^a   Andresen, T L ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

Author keywords

C5a; Cancer; Complement system; Nanoparticles

Indexed keywords

CARBON NANOTUBE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; CYTOTOXIC AGENT; DOXORUBICIN; IMMUNOGLOBULIN G1; LIPOSOME; MACROGOL; MONOCLONAL ANTIBODY; NANOPARTICLE; POLOXAMER; RECOMBINANT PROTEIN;

AIRWAY OBSTRUCTION; CANCER CELL; CELL INFILTRATION; COMPLEMENT ACTIVATION; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DYSPNEA; FLUSHING; HUMAN; HYPOTENSION; LETTER; MALAISE; NANOMEDICINE; NANOTECHNOLOGY; PRIORITY JOURNAL; SIDE EFFECT; STEREOSPECIFICITY; TUMOR GROWTH;

CELL GROWTH PROCESSES; COMPLEMENT SYSTEM PROTEINS; DISEASE PROGRESSION; HUMANS; NANOMEDICINE; NANOTECHNOLOGY; NEOPLASMS;

EID: 64149086047     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2009.02.014     Document Type: Letter

References (20)

1. Al-Hanbali O., Rutt K.J., Sarker D.K., Hunter A.C., and Moghimi S.M. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J. Nanosci. Nanotechnol. 6 (2006) 3126-3133
2. ®): possible role in hypersensitivity reactions. Ann. Oncol. 14 (2003) 1430-1437
3. Gbadamosi J.K., Hunter A.C., and Moghimi S.M. PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance. FEBS Lett. 532 (2002) 338-344
4. Gelderman K.A., Kuppen P.J., Okada N., Fleuren G.J., and Gorter A. Tumor-specific inhibition of membrane-bound complement regulatory protein Crry with bispecific monoclonal antibodies prevents tumour out-growth in a rat colorectal cancer lung metastases model. Cancer Res. 64 (2004) 4366-4372
5. Gelderman K.A., Tomlinson S., Ross G.D., and Gorter A. Complement function in mAb-mediated cancer immunotherapy. Trend. Immunol. 25 (2004) 158-164
6. Hamad I., Hunter A.C., Rutt K.J., Liu Z., Dai H., and Moghimi S.M. Complement activation by PEGylated carbon nanotubes is independent of C1q and alternative pathway turnover. Mol. Immunol. 45 (2008) 3797-3803
7. Hamad I., and Moghimi S.M. Critical isues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug. Exp. Opin. Drug Deliv. 5 (2008) 205-219
8. Liu Z., Chen K., Davis C., Sherlock S., Cao Q., Chen X., and Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res. 68 (2008) 6652-6660
9. Markiewski M.M., DeAngelis R.A., Benencia F., Ricklin-Lichtsteiner S.K., Koutoulaki A., Gerard G., Coukos G., and Lambris J.D. Modulation of the antitumor immune response by complement. Nat. Immunol. 9 (2008) 1225-1235
10. Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E., and Lambris J.D. Complement and coagulation: strangers or partners in crime?. Trend. Immunol. 28 (2007) 184-192
11. Moghimi S.M. Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. Anti-Cancer Agent. Med. Chem. 6 (2006) 553-561
12. Moghimi S.M., Hunter A.C., and Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53 (2001) 283-318
13. Moghimi S.M., Hamad I., Andresen T.L., Jørgensen K., and Szeneni J. Methylation of the phosphate oxygen moiety of phospholipid-methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-mediated complement activation and anaphylatoxin production. FASEB J. 20 (2006) 2591-2593
14. Moghimi S.M., and Murray J.C. Poloxamer-188 revisited: a potentially valuable immune modulator?. J. Natl. Cancer Inst. 88 (1996) 766-768
15. Moghimi S.M., and Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42 (2003) 463-478
16. Reddy S.T., van der Vlies A.J., Simeoni E., Angeli V., Randolph G.J., O'Neill C.P., Lee L.K., Swartz M.A., and Hubbell J.A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25 (2007) 1159-1164
17. Ricklin D., and Lambris J.D. Complement-targeted therapeutics. Nat. Biotechnol. 25 (2007) 1265-1275
18. Simberg D., Duza T., Park J.H., Essler M., Pilch J., Zhang L.L., Derfus A.M., Yang M., Hoffman R.M., Bhatia S., Sailor M.J., and Rouslahti E. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 932-936
19. Szebeni J. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2005) 106-121
20. Varela J.C., Imai M., Atkinson C., Ohta R., Rapisardo M., and Tomlinson S. Modulation of protective T cell immunity by complement inhibitor expression on tumour cells. Cancer Res. 68 (2008) 6734-6742